China-based ReLive Biotechnologies, Ltd. has acquired Germany-based Co.Don AG. Terms of the deal were not disclosed.
ReLive Biotechnologies is taking over the global patent rights of Spherox and Chondrosphere. Spherox is one of two authorized cell therapies for the regenerative treatment of articular cartilage defects globally.
Co.Don AG is a biopharmaceutical company that develops, produces and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide.
According to data captured in the LevinPro HC database, this acquisition represents the 16th Biotechnology deal of 2023. There were 141 Biotechnology transactions reported in 2022.
